Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance – Yahoo Finance


Salt Lake City, Utah–(Newsfile Corp. – September 13, 2022) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company’s capital markets strategy and planning.
“Melissa brings to our company more than 15 years of financial and operational experience in both clinical and commercial-stage biotech and life science companies,” said Brian M. Strem, Ph.D., President and CEO of Kiora. “This experience will be invaluable to our goals of advancing our development pipeline and supporting our next phase of growth.”
Prior to joining Kiora, Melissa served as Executive Director of Finance and Corporate Treasurer for Neomorph, where she managed the company’s finance and accounting functions. She also served as Director of Finance and Accounting at Omniome, building the accounting and finance infrastructure and managing the company’s financial operations. Prior to Omniome, she spent nine years at Caris Life Sciences, serving in various leadership roles including Director of Finance and Accounting, Director of Financial Planning and Analysis and Senior Director of Sales Operations. She began her professional career in public accounting at Clifton Gunderson and later moved to Ernst and Young as an Audit Manager. Melissa is a Certified Public Accountant and holds a B.S. in Accounting from the University of Arizona.
“I am pleased to be able to join the team and help advance their pipeline of new treatments for underserved ophthalmic diseases,” said Melissa Tosca, newly appointed EVP of Finance. “It is an exciting time for Kiora as they begin a first-in-human study for what could be a transformative treatment to restore vision in patients with a rare form of blindness.”
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis (“OPRA”). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Forward-Looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora’s development-stage products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading “Risk Factors” contained in Kiora’s Amendment No. 1 to Annual Report on Form 10-K/A filed with the SEC on July 7, 2022 or described in Kiora’s other public filings. Kiora’s results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.
Investor Contact
Francina Agosti, PhD
(617) 546-0742
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/136901
Related Quotes
Nvidia Corp. faces a very different environment versus two years ago when it last launched a new chip architecture, one where demand is falling and its stock price has been more than halved over the year.
You can't guess the bottom. But a bargain is a bargain.
We’re getting toward the tail end of the year, and it’s time to start deciding just how to allocate the portfolio for a solid year-end return. In a recent note from JPMorgan, focused on the energy sector, 5-star analyst Arun Jayaram recommended oil and gas producers as likely to beat the overall markets going forward. Getting quickly to the bottom line, Jayaram states, "We remain fans of the longer-term story for natural gas driven by a growing global demand for low cost U.S. gas exports." With
Figma's stats are extraordinary. There's a good chance — and we'll know in a few years — that the acquisition was worth it.
Time's almost up on ultra-low rates, so don't be caught off guard.
Indian industrialist Gautam Adani surpassed the Amazon founder to become the world’s second-richest person, trailing only Elon Musk.
(Bloomberg) — From a start guarding trains full of metal from thieves on freezing winter nights, He Jinbi built a copper trading house so powerful that it handles one of every four tons imported into China.A born trader with an infectious sense of humor, the 57-year-old grew Maike Metals International Ltd. through the rough-and-tumble rush for commodities in the early 2000s, to become a key conduit between China’s industrial heartlands and global merchants like Glencore Plc.Now Maike is sufferi
It's no secret that investors are worried about runaway inflation. Cathie Wood and Elon Musk see deflation as the bigger threat.
Meta Platforms (NASDAQ: META) is spending billions to transition into a metaverse company. Does that make it an excellent time to buy the stock now? This video answers that question using my simplified six-step framework.
E-commerce company Shopify (NYSE: SHOP) was a big winner during COVID-19, but the stock has fallen from grace, down a whopping 80% from its peak. Investors may uncover more questions than answers as they dig into Shopify. Here is what's going on and why investors shouldn't assume that Shopify is cheap just because the stock's fallen so far.
Most stocks are having a lousy year in 2022. Here are a dozen that don't deserve being this deep in the red.
It's been a rough year in the stock market, especially for fintech investors. High inflation and rising interest rates put investors on edge, ramping up market volatility. One company feeling the pain is SoFi Technologies (NASDAQ: SOFI), the fintech that was a hot stock when it first went public in 2020.
Essentially, it's having a killer business model that doesn't need to change much to stay profitable, relevant, and rewarding for shareholders as the years roll by. With that thought in mind, let's examine a trio of stocks worth buying and holding forever — and you've probably already heard of all three. Abbott Laboratories (NYSE: ABT) is a no-brainer stock for indefinite holding because it's always growing its dividend and making share repurchases to boost returns.
Investors have spent the past few months worrying about what difficult macroeconomic conditions and a slowing global economy might mean for corporate profits. Late Thursday, FedEx (NYSE: FDX) sounded the alarm that those concerns are justified. FedEx expects to miss Wall Street's estimates by more than 30% in the recently completed quarter, and it warned the current quarter will be just as bad.
Despite strong fundamentals, sellers have knocked Costco stock lower ahead of its quarterly earnings report.
If just two themes have defined the stock market in 2022, those themes would be stock splits and the bear market. Both have disproportionately affected the technology sector, with some of the largest tech companies in the U.S. opting for stock splits to reduce their high share prices, and the Nasdaq-100 tech index bearing the brunt of the broader market losses. Palo Alto Networks (NASDAQ: PANW), Shopify (NYSE: SHOP), and Tesla (NASDAQ: TSLA) have all conducted stock splits this year, and each stock has touched its 52-week low within the last four months.
Corporate landlords still like the space. Take advantage.
A profit warning from FedEx, an expensive acquisition for Adobe and fear of the Federal Reserve all weighed on the stock market.
Facebook was a member of the exclusive $1 trillion club a year ago, but it's fallen a long way since then.
S&P 500 dividend standout Devon Energy leads this weekend's watch list of stocks near buy points in a tough market.

source


Leave a Reply

Your email address will not be published.